Here’s what you should know:
1. Glenmark could use the compound as a monotherapy or in combination with approved treatments.
2. The companies didn’t disclose the deal’s terms.
3. The compound is currently in a phase II proof-of-concept study.
4. APC Therapeutics Co-Founders Vinod Patel and Venkateshwar Reddy said to GEN, “Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer.”
More articles on gastroenterology:
Exact Sciences pockets $245M in stock sale & more — 6 GI company key notes
The biggest problem in gastroenterology & how to fix it — Texas Digestive Disease Consultants CEO Dr. James Weber sheds insight
GI practice to know: Illinois Gastroenterology Group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
